You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Immunologic marker levels in comparative groups: surviving vs. non-surviving, ARDS vs. non-ARDS

From: Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis

  Non-Surviving Patients [total n = 16] (CI) Surviving Patients [total n = 14] (CI) Pvalue Non-ARDS Patients [total n = 13] (CI) ARDS Patients [total n = 17] (CI) Pvalue
HMGB-1 (ng/mL)a 11.76 [13] (-5.65-60) 6.78 [12] (4.5-17.66) .44 10.11 [11] (4.64-18.97) 11.11 [14] (-4.83-55.51) .64
RAGE (MFI)a 88.88 [15] (55.9-150.8) 116.7 [14] (51.9-456.2) .21 98.01 [12] (6.68-492.31) 90.63 [17] (75.55-173.27) .94
sRAGE (pg/mL)a 3236 [15] (2312-3673) 1037 [13] (912.8-2769) .058 1829.75 [13] (1079-2629) 3296 [15] (2168-3793) .058
  1. HMGB-1, high mobility group box -1, RAGE, receptor for advanced glycation end products; sRAGE, soluble RAGE; MFI, mean fluorescence intensity
  2. [n] Expresses the numeral of results analyzed, from the total number
  3. aData is expressed as median (CI)